Heart failure - The importance of ethnicity

European Journal of Heart Failure

Volumn 6, Issue 7, 2004, Pages 831-843

  Sosin, Michael D ^a   Bhatia, Gurbir S ^a   Davis, Russell C ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Epidemiological; Mechanistic; Therapeutic

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; EPLERENONE; HYDRALAZINE; ISOSORBIDE DINITRATE; LOSARTAN; METOPROLOL; NITRIC ACID DERIVATIVE; NITRIC OXIDE; OMAPATRILAT; PRAZOSIN; RENIN; SPIRONOLACTONE;

ADRENERGIC SYSTEM; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; COUGHING; DIABETES MELLITUS; DRUG FATALITY; ENDOTHELIUM CELL; ETHNOLOGY; EUROPE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; THROMBOSIS; UNITED KINGDOM; VALVULAR HEART DISEASE;

CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DECISION MAKING; DISEASE MANAGEMENT; EUROPE; FORECASTING; HEALTH SERVICES ACCESSIBILITY; HEART FAILURE, CONGESTIVE; HUMANS; RISK FACTORS; UNITED STATES;

EID: 8844284467     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2003.11.019     Document Type: Review

References (127)

1. Hobbs F.D.R., Kenkre J.E., Roalfe A.K., Davis R.C., Hare R., Davies M.K. Impact of heart failure and left ventricular systolic dysfunction on quality of life. Eur Heart J. 23:2002;1867-1876
2. Sutton G.C. Epidemiological aspects of heart failure. Am Heart J. 120:1990;1538-1540
3. Stewart S., Jenkins A., Buchan S., McGuire A., Capewell S., McMurray J.J.V. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 4:2002;361-371
4. Gillum R.F. Heart and stroke facts. Am Heart J. 126:1993;1042-1047
5. Bonneaux L., Barendregt J.J., Meeter K., Bonsel G.J., Van der Maas P.J. Estimating clinical morbidity due to ischaemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health. 84:1994;20-28
6. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham heart study. Circulation. 106:2002;3068-3072
7. McKee P.A., Castelli W.P., McNamara W.B. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 285:1971;1441-1446
8. Cowie M.R., Wood D.A., Coats J.S., Thompson S.G., Poole-Wilson P.A., Suresh V., et al. Incidence and aetiology of heart failure: a population based study. Eur Heart J. 20:1999;421-428
9. Data fact sheet: congestive heart failure in the United States: a new epidemic. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1996
10. Dries D.L., Exner D.V., Gersh B.J., Cooper H.A., Carson P.E., Domanski M.J. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 340:1999;609-616. Erratum, N Engl J Med 1999;341:298.
11. Rathore S.S., Foody J.M., Wang Y., et al. Race, quality of care, and outcomes of elderly patients hospitalised with heart failure. J Am Med Assoc. 289:2003;2517-2524
12. Dunlap S.H., Mallemala S., Sueta C.A., et al. Survival rates are similar between African American and white patients with heart failure. Am Heart J. 146:2003;265-272
13. Lip G., Zarifis J., Beevers D.G. Acute admissions with heart failure to a district general hospital serving a multiracial population. Int J Clin Pract. 51:1997;223-227
14. Chaturvedi N. Ethnic differences in cardiovascular disease. Heart. 89:2003;681-686
15. Lipshultz S.E., Sleeper L.A., Towbin J.A., Lowe A.M., Orav E.J., Cox G.F., et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 348:2003;1647-1655
16. Coughlin S.S., Labenberg J.R., Tefft M.C. Black-white differences in idiopathic dilated cardiomyopathy: the Washington DC dilated Cardiomyopathy Study. Epidemiology. 4:1993;165-172
17. Coughlin S.S., Neaton J.D., Sengupta A., Kuller L.H. Predictors of mortality from idiopathic dilated cardiomyopathy in 356 222 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol. 139:1994;166-172
18. Veasy L.G., Tani L.Y., Hill H.R. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr. 124:1994;9-16
19. Mahgoub M.A., Abd-Elfattah A.S. Diabetes mellitus and cardiac function. Mol Cell Biochem. 180:(1-2):March 1998;59-64
20. Beta Blockers Evaluation Survival Trial Investigators. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 42:2003;914-922
21. Duan J., Zhang H.Y., Adkins S.D., Ren B.H., Norby F.L., Zhang X., et al. Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: role of Akt and RhoA. Am J Physiol Endocrinol Metab. 284:2003;E366-E376
22. Abate N., Chandalia M. The impact of ethnicity on type 2 diabetes. J Diabetes Complications. 17:2003;39-58
23. Makin A.J., Silverman S.H., Lip G.Y. Ethnicity and peripheral vascular disease. Int J Clin Pract. 56:2002;645-648
24. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study, XII. Differences between Asian, Afro-Caribbean and White Caucasian type 2 diabetic patients at diagnosis of diabetes. Diabetic Medicine 1994;11:670-677
25. Hypertension Detection and Follow Up Program Cooperative Group. Race, education and prevalence of hypertension. Am J Epidemiol. 106:1977;351-361
26. Cooper E.S., Kuller L.H., Saunders E., Martinez-Maldonado M., Caplan L.R., Yatsu F.M., et al. Cardiovascular diseases and stroke in African-Americans and other racial minorities in the United States: a statement of health professionals. Circulation. 83:1991;1462-1480
27. Stamler J., Rhomberg P., Schonberger J.A., Shekelle R.B., Dyer A., Shekelle S., et al. Multivariate analysis of the relationship of seven variables to blood pressure. Journal of Chronic Disease. 28:1975;527-548
28. Meade T.W., Brosovic M., Chakraborti R., Haines A.P., North W.R.S., Stirling Y. Ethnic group comparisons of variables associated with ischaemic heart disease. Br Heart J. 40:1978;789-795
29. Cooper R.S., Liao Y., Rotimi C. Is hypertension more severe among US blacks, or is severe hypertension more common? Ann Epidemiol. 6:1996;173-180
30. Mayet J., Shahi M., Foale R.A., Poulter N.R., Sever P.S., McG Thom S.A. Racial differences in cardiac structure and function in essential hypertension. Brit Med J. 308:1994;1011-1014
31. Sullivan J.M. Salt-sensitivity: definition, conception, methodology, and long-term issues. Hypertension. 17:(suppl. 1):1991;I61-I68
32. Light K.C., Sherwood A., Turner J.R. High cardiovascular reactivity to stress: a predictor of later hypertension development. Turner J.R., Sherwood A., Light K.C. Individual differences in cardiovascular response to stress. 1992;281-293 Plenum Press, New York, NY
33. Thomas J., Semenya K., Thomas C.B., Thomas D.J., Neser W.B., Pearson T.A., et al. Precursors of hypertension in black compared to white medical students. J Chronic Dis. 40:(7):1987;721-727
34. Murphy M.B., Nelson K.S., Oliner C.M., Elliot W.J. Higher nocturnal blood pressure in normal and hypertensive blacks compared with whites. Circulation. 48:1988;2268A
35. Harshfield G.A., Hwang C., Grim C. The circadian variation of blood pressure in blacks: influence of age, gender and activity. J Hum Hypertens. 4:1990;43-47
36. Harshfield G.A., Alpert B.S., Willey E.S., Somes G.W., Murphy J.K., Dupaul L.M. Race and gender influence ambulatory blood pressure patterns of adolescents. Hypertension. 14:1989;598-603
37. Hammond I.W., Alderman M.H., Devereux R.B., Luras E.M., Laragh J.H. Contrast in cardiac anatomy and function between black and white patients with hypertension. J Natl Med Assoc. 76:1984;247-255
38. Calhoun D.A., Mutinga M.L., Collins A.S., Wyss J.M., Oparil S. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension. 22:1993;801-805
39. Rutledge D.R., Cardozo L., Steinberg J.D. Racial differences in drug response: isoproterenol effects on heart rate in healthy males. Pharm Res. 6:1989;182-185
40. Dimsdale J.E., Graham R.M., Ziegler M.G., Zusman R.M., Berry C.C. Age, race, diagnosis, and sodium effects on the pressor response to infused norepinephrine. Hypertension. 10:1987;564-569
41. Duey W.J., Bassett D.R. jr, Walker A.J., et al. Cardiovascular and plasma catecholamine response to static exercise in normotensive blacks and whites. Ethn Health. 2:1997;127-136
42. Sherwood A., Hinderliter A.L. Responsiveness to alpha- and beta-adrenergic receptor agonists: effect of race in borderline hypertensive compared to normotensive men. Am J Hypertens. 6:1993;630-635
43. Mills P.J., Dimsdale J.E., Ziegler M.G., Nelesen R.A. Racial differences in epinephrine and beta 2-adrenergic receptors. Hypertension. 25:1995;88-91
44. Sudhir K., Forman A., Yi S.L., et al. Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. Hypertension. 29:1997;1083-1090
45. Stein M., O'Maley K., Kilfeater S. Ethnic differences in cyclic AMP accumulation: effect on alpha2, beta2, and prostanoid receptor responses. Clin Pharmacol Ther. 47:1990;360-365
46. Isaacs K.D., Russouw J., du Plooy W.J. Differences in lymphocyte beta2-adrenoceptors clearly could explain reported differences in basal lymphocyte cAMP production in two ethnic groups. Med Sci Res. 21:1993;313-314
47. Lang C.C., Stein M., He H.B., Belas F.J., Blair I.A., Wood M., et al. Blunted blood pressure response to central sympathoinhibition in normotensive blacks. Hypertension. 30:1997;157-162
48. Lang C.C., Stein M., Nelson R., He H.B., Belas F.J., Blair I.A., et al. Sympathoinhibitory response to clonidine is blunted in patients with heart failure. Hypertension. 30:1997;392
49. Lang C.C., Stein C.M., Brown R.M., Deegan R., Nelson R., He H.B., et al. Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med. 333:1995;155-160
50. Francis G.S., Goldsmith S.R., Levine T.B., Olivari M.T., Cohn J.N. The neurohormonal axis in congestive heart failure. Ann Intern Med. 101:1984;370-377
51. Pouleur H., Benedict C.R., Rousseau M.R. Neurohormones in patients with ischemic left ventricular dysfunction. Crdiovasc Drugs Ther. 8:1994;313-317
52. Rector T.S., Olivari M.T., Levine T.B., Francis G.S., Cohn J.N. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J. 114:1987;148-152
53. Cohn J.N., Johnson G.R., Shabetai R., Oeb H., Tristani F., Rector T.S., et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 87:(suppl. VI):1993;VI-5-VI-16
54. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415
55. Verma S., Anderson T.J. Fundamentals of Endothelial function for the clinical cardiologist. Circulation. 105:2002;546-549
56. Kubo S.H., Rector T.S., Bank A.J., Williams R.E., Heifetz S.M. Endothelium-dependent vasodilatation is attenuated in patients with heart failure. Circulation. 84:1991;1589-1596
57. Chambers J.C., McGregor A., Jean-Marie J., Kooner J.S. Abnormalities of vascular endothelial function may contribute to increased coronary heart disease risk in UK Indian Asians. Heart. 81:1999;501-504
58. Jones D.S., Andrawis N.S., Abernethy D.R. Impaired endothelial-dependent forearm vascular relaxation in black Americans. Clin Pharmacol Ther. 65:1999;408-412
59. Khan D.F., Duffy S.J., Tomasian D., et al. Effects of black race on forearm resistance vessel function. Hypertension. 40:2002;195-201
60. Adeniyi A., Folsom A.R., Brancati F.L., Desvorieux M., Pankow J.S., Taylor H. Incidence and risk factors for cardiovascular disease in African Americans with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. J Natl Med Assoc. 94:2002;1025-1035
61. Yanagisawa M., Kurihara H., Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415
62. Jilma B., Szalay T., Dirnberger E., Eichler H.G., Stohlawetz P., Schwarzinger I., et al. Effects of endothelin-1 on circulating adhesion molecules in man. Eur J Clin Invest. 27:1997;850-856
63. Krejcy K., Eichler H.G., Jilma B., Kapiotis S., Wolzt M., Zanaschka G., et al. Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo. Can J Physiol Pharmacol. 74:1996;9-14
64. Davenport A.P., Ashby M.J., Easton P., Ella S., Bedford J., Dickerson C., et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison of levels in patients with essential hypertension and normotensive control subjects. Clin Sci (Colch). 78:1990;261-264
65. Kohno M., Yasunari K., Murakawa K., Yokokawa K., Horio T., Fukui T., et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med. 88:1990;614-618
66. Shichiri M., Hirata Y., Ando K., Emori T., Ohta K., Kimoto S., et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension. 15:1990;493-496
67. Schiffrin E.L., Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens. 4:1991;303-308
68. Evans R.R., Phillips B.G., Singh G., Bauman J.L., Gulati A. Racial and gender differences in endothelin-1. Am J Cardiol. 78:1996;486-488
69. Treiber FA, Jackson RW, Davis H, Pollock J, Kapuku G, Mensah GA et al. Racial differences in endothelin-1 at rest and in response to acute stress in adolescent males
70. Ergul S., Parish D.C., Puett D., Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 28:1996;652-655
71. Ergul A., Shoemaker K., Puett D., Tackett R.L. Gender differences in the expression of endothelin receptors in human saphenous veins in vitro. J Pharmacol Exp Ther. 285:1998;511-517
72. Ergul A., Tackett R.L., Puett D. Distribution of endothelin receptors in saphenous veins of African Americans: implications of racial differences. J Cardiovasc Pharmacol. 34:1999;327-332
73. Barton M., Vos I., Shaw S., Boer P., D'Uscio L.V., Gröne H.-J., et al. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol. 11:2000;835-846
74. Kalra P.R., Moon J.C., Coats A.J. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol. 85:2002;195-197
75. Uretsky B.F., Thygesen K., Armstrong P.W., Cleland J.G., Horowitz J.D., Massie B.M., et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation. 102:2000;611-616
76. Mattson D.L., Lu S., Nakanishi K., Papanek P.E., Cowley A.W. Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol. 266:1994;H1918-H1926
77. Hirooka Y., Imaizumi T., Masaki H., et al. Captopril improves impaired endothelium dependent dilatation in hypertensive patients. Hypertension. 20:1992;175-180
78. Taddei S., Virdis A., Mattei P., et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertension patients. Circulation. 94:1996;1298-1303
79. Higashi Y., Nakagawa K., Kimura M., et al. Circadian variation of blood pressure and endothelial function in patients with essential hypertension: a comparison of dippers and non-dippers. J Am Coll Cardiol. 40:2002;2039-2043
80. Houghton J.L., Philbin E.F., Strogatz D.S., et al. The presence of African American race predicts improvement in coronary endothelial function after supplementary L-Arginine. J Am Coll Cardiol. 39:2002;1314-1322
81. Chen P.Y., Sanders P.W. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. Hypertension. 31:1998;918-924
82. Taner C.B., Severson S.R., Best P.J., Lerman A., Miller V.M. Treatment with endothelin-receptor antagonists increases NOS activity in hypercholesterolemia. J Appl Physiol. 90:2001;816-820
83. Cardillo C., Kilcoyne C.M., Cannon R.O., Panza J.A. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation. 99:1999;90-95
84. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med. 345:2001;1689-1697
85. Schrier R.W., Abraham W.T. Hormones and haemodynamics in heart failure. N Engl J Med. 341:1999;577-585
86. Swedberg K., Eneroth P., Kjekshus J., et al. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol. 66:1990;40D-44D
87. Brunner H.R., Sealey J.E., Laragh J.H. Renin as a risk factor in essential hypertension: more evidence. Am J Med. 55:1973;295
88. Rowlands D.B., DeGiovanni J., McLeay R.A.B., Watson R.D.S., Stallard T.J., Littler W.A. Cardiovascular response in black and white hypertensives. Hypertension. 4:1982;817-820
89. Carson P., Ziesche S., Johnson G., Cohn J.N. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail. 5:1999;178-187
90. Sosin M., Bhatia G., Lip G.Y.H. Should Chronic Heart Failure be treated with antithrombotic drugs? HeartDrug. 2:2002;295-302
91. Ridker P.M., Hennekens C.H., Cerksus A., Stampfer M.J. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation. 90:1994;2236-2240
92. Pieper C.F., Rao K.M., Currie M.S., Harris T.B., Cohen H.J. Age, functional status and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Ger Biol Sci Med Sci. 55:2000;M649-M657
93. Upshaw C.B. Jr. Reduced prevalence of atrial fibrillation in black patients compared with white patients attending an urban hospital: an electrocardiographic study. J Natl Med Assoc. 94:2002;204-208
94. Gibbs C.R., Lip G.Y.H. Atrial fibrillation and ethnicity. Circulation. 21:1999;e153
95. Vaccarino V., Gahbauer E., Kasl S.V., Charpentier P.A., Acampora D., Krumholz H.M. Differences between African Americans and whites in the outcome of heart failure: evidence for a greater functional decline in African Americans. Am Heart J. 143:2002;1058-1067
96. Lip G.Y., Kamath S., Jafri M., Mohammed A., Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. Stroke. 33:2002;238-242
97. Materson B.J., Reda D.J., Cushman W.C., et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med. 328:1993;914-921. [Erratum, N Engl J Med 1994;330:1689.]
98. Saunders E., Weir M.R., Kong B.W., Hollifield J., Gray J., Vertes V., et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 150:1990;1707-1713
99. Wassertheil-Smoller S., Oberman A., Blaufox M.D., Davis B., Langford H. The Trial of Antihypertensive Interventions and Management (TAIM) Study. Final results with regard to blood pressure, cardiovascular risk, and quality of life. Am J Hypertens. 5:1992;37-44
100. The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;995-1003
101. The Life Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 359:2002;1004-1010
102. Exner D.V., Dries D.L., Domanski M.J., Cohn J.N. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med. 344:2001;1351-1357
103. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). 2001. ACC Web site. Available at: (http:/www.acc.org/clinical/guidelines/failure/hf_index.htm)
104. Cubeddu L.X., Aranda J., Singh B., et al. A comparison of verapamil and propranolol for the initial treatment of hypertension: racial differences in response. J Am Med Assoc. 256:1986;2214-2221
105. Freudenberger R., Kalman J., Mannino M., Buchholz-Varley C., Ocampo O., Kukin M. Effect of race in the response to metoprolol in patients with congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol. 80:1997;1372-1374
106. Beta Blockers Evaluation Survival Trial Investigators. A trial of the beta blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 334:2001;1659-1667
107. Yancy C.W., Fowler M.B., Colucci W.S., et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 344:2001;1358-1365
108. Pitt B., Zannad F., Remm W.J., Cody R., Castaigne A., Perez A., et al. for the Randomised Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 341:1999;709-717
109. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 348:2003;1309-1321
110. Flack J.M., Oparil S., Pratt J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol. 41:(7):2 April 2003;1148-1155
111. Campese V.M., Lasseter K.C., Ferrarrio C.M., et al. Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive patients. Hypertension. 38:2001;1342-1348
112. Rouleau J.L., Pfeffer M.A., Stewart D.J., et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 356:2000;615-620
113. Packer M., Califf R.M., Konstam M.A., et al. Comparison of omnapatrilat and enalapril in patients with chronic heart failure: the Omnapatrilat versus Enalapril Randomised Trial of Utility in Reducing Events (OVERTURE). Circulation. 106:2002;920-926
114. Coats A.J. Omapatrilat-the story of Overture and Octave. Int J Cardiol. 86:2002;1-4
115. Franciosa J.A., Taylor A.L., Cohn J.N., et al. African-American Heart Failure Trial (A-HeFT): rationale, design and methodology. J Card Fail. 8:2002;128-135
116. Barakat K., Wells Z., Ramdhany S., Mills P.G., Timmis A.D. Bangladeshi patients present with non-classic features of acute myocardial infarction and are treated less aggressively in east London, UK. Heart. 89:2003;276-279
117. Feder G., Crook A.M., Magee P., Banerjee S., Timmis A.D., Hemingway H. Ethinic differences in invasive management of coronary disease: prospective cohort study of patients undergoing angiography. Brit Med J. 324:2002;511-516
118. Ghali J. Race, ethnicity, and heart failure. J Card Fail. 8:2002;387-389
119. Davies M.K., Hobbs F.D., Davis R.C., Kenkre J.E., Roalfe A.K., Hare R., et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: a population based study. Lancet. 358:2001;439-444
120. Morgan S., Smith H., Simpson J., et al. Prevalence and clinical characteristics of left-ventricular systolic dysfunction amongst elderly patients in a general practice setting. Brit Med J. 318:1999;368-372
121. McDonagh T.A., Morrison C.E., Lawrence A., Ford I., Tunstall-Pedoe H., McMurray J.J., et al. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet. 350:1997;829-833
122. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 327:1992;685-691
123. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 325:1991;293-302
124. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival And Ventricular Enlargement Trial. N Engl J Med. 327:1992;669-677
125. The CONSENSUS Trial Study Group. Effects of Enalapril on mortality in severe congestive heart failure. N Engl J Med. 316:1987;1429-1435
126. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:1999;2001-2007
127. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II. Lancet. 353:1999;9-13